New England Biolabs Expands Genomics Toolkit with seqWell Transposase Partnership
Event summary
- New England Biolabs (NEB) and seqWell launched a strategic partnership on October 15, 2026, with NEB gaining co-exclusive rights to sell and manufacture seqWell's TnX Transposase (Unloaded).
- TnX Transposase (Unloaded) enables custom transposome assembly for flexible, platform-agnostic genomic workflows.
- NEB will integrate TnX into its existing product portfolio, addressing lot variability issues common in unloaded Tn5 transposases.
- The product is now available through NEB's distribution channels with optimized protocols for research applications.
The big picture
This partnership aligns with the growing demand for scalable, high-performance genomic tools, particularly as single-cell and multi-omics research expand. NEB's manufacturing expertise and seqWell's transposase technology create a formidable combination in the competitive next-generation sequencing (NGS) library preparation space. The deal underscores the industry's shift toward modular, customizable solutions for complex genomic workflows.
What we're watching
- Market Adoption
- How quickly researchers will integrate TnX Transposase into existing workflows, particularly in single-cell and custom assay development.
- Competitive Positioning
- Whether NEB can leverage its manufacturing scale to outpace competitors in the transposase market.
- Technical Validation
- The pace at which third-party studies confirm TnX's reproducibility and performance advantages over existing solutions.
Related topics
